13 assets in Lymphoid Leukemia

Therapeutic assets addressing Lymphoid Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ibrutinib Lymphoid Leukemia	Loxo Oncology, Inc.	P4	BBB (72)
Pirtobrutinib Lymphoid Leukemia	Loxo Oncology, Inc.	P3	BB (66)
Cyclophosphamide Lymphoid Leukemia	Dana-Farber Cancer Institute	P2	B (60)
Cucart19 Lymphoid Leukemia	Chi Kong Li	P2	CCC (53)
Mosunetuzumab Lymphoid Leukemia	M.D. Anderson Cancer Center	P2	CCC (53)
Bms-986345 Lymphoid Leukemia	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (47)
Duvelisib Lymphoid Leukemia	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (47)
Autologous Tricar-All T-Cells Lymphoid Leukemia	Baylor College of Medicine	P1	CC (43)
ins19 car-t cells Lymphoid Leukemia	Beijing Immunochina Medical Science & Technology Co., Ltd.	P1	CC (43)
mgd024 Lymphoid Leukemia	MacroGenics	P1	CC (43)
Neovax Lymphoid Leukemia	Dana-Farber Cancer Institute	P1	CC (43)
Pembrolizumab Lymphoid Leukemia	Dana-Farber Cancer Institute	P1	CC (43)
ms-553 Lymphoid Leukemia	Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.	P1/2	D (30)